Gene transfer: the challenge of regulated gene expression

Gene therapy is expected to have a major impact on human healthcare in the future. However, precise regulation of therapeutic gene expression in vivo is still a challenge. Natural and synthetic enhancer-promoters (EPs) can be utilized to drive gene transcription in a temporal, spatial or environmental signal-inducible manner in response to heat shock, hypoxia, radiation, chemotherapy, epigenetic agents or viral infection. To allow tightly regulated expression, a regulatable gene-expression system can also be implemented. Most of these systems are based on small molecule (drug)-responsive artificial transactivators. In this review, we aim to provide a brief overview of the classes of EPs and regulatable systems, along with lessons learned from these studies. We highlight the potential applications in gene transfer, gene therapy for cancer and genetic disease and the future challenges for clinical applications.

[1]  M. Fussenegger,et al.  An engineered epigenetic transgene switch in mammalian cells , 2004, Nature Biotechnology.

[2]  Akseli Hemminki,et al.  Tissue-specific promoters for cancer gene therapy , 2004, Expert opinion on biological therapy.

[3]  M. DePamphilis,et al.  Specific transcription factors stimulate simian virus 40 and polyomavirus origins of DNA replication , 1992, Molecular and cellular biology.

[4]  D. Nettelbeck,et al.  Insulated hsp70B′ promoter: stringent heat‐inducible activity in replication‐deficient, but not replication‐competent adenoviruses , 2008, The journal of gene medicine.

[5]  Jonathan L. Linehan,et al.  Efficient and Stable Transgene Expression in Human Embryonic Stem Cells Using Transposon‐Mediated Gene Transfer , 2007, Stem cells.

[6]  J. Gu,et al.  Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  C. Halbert,et al.  High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. , 2007, Human gene therapy.

[8]  M. Kanaoka,et al.  Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. , 2007, Human gene therapy.

[9]  L Ji,et al.  A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax , 2000, Gene Therapy.

[10]  J. Rivas,et al.  Interleukin-12 inhibits liver-specific drug-inducible systems in vivo , 2008, Gene Therapy.

[11]  Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy , 2008, Cancer Gene Therapy.

[12]  N. Knuckey,et al.  Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures , 2006, Brain Research.

[13]  T. Fujiwara,et al.  Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. , 2008, Uirusu.

[14]  Hongyan Dong,et al.  Hypoxic response elements control expression of human vascular endothelial growth factor165 genes transferred to ischemia myocardium in vivo and in vitro , 2007, The journal of gene medicine.

[15]  Jane Worthington,et al.  p21(WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy , 2007, Gene Therapy.

[16]  A. Annoni,et al.  Immune responses to lentiviral vectors. , 2007, Current gene therapy.

[17]  P. Overbeek,et al.  Tissue-specific expression in transgenic mice of a fused gene containing RSV terminal sequences. , 1986, Science.

[18]  M. Lotze,et al.  Second‐generation tetracycline‐regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness , 2004, The journal of gene medicine.

[19]  G. Rubanyi,et al.  Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle , 2004, The journal of gene medicine.

[20]  J. Mallet,et al.  Lentiviral vectors mediate nonimmunosuppressive rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of transcription and exocytosis. , 2008, Human gene therapy.

[21]  K. Jooss,et al.  An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  B. Geest,et al.  Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer , 2008, Gene Therapy.

[23]  A. Kingsman,et al.  An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer , 1999, Gene Therapy.

[24]  R. Martuza,et al.  Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. , 2006, Cancer research.

[25]  T. Fujiwara,et al.  Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. , 2007, Current cancer drug targets.

[26]  J. Paton,et al.  Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain , 2008, The journal of gene medicine.

[27]  P. Friedlander,et al.  Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. , 2003, Cancer research.

[28]  Rong Li,et al.  Construction of an artificial intercellular communication network using the nitric oxide signaling elements in mammalian cells. , 2008, Experimental cell research.

[29]  Jun Ma,et al.  GAL4-VP16 is an unusually potent transcriptional activator , 1988, Nature.

[30]  N. Nakatsuji,et al.  Establishment of the Gene‐Inducible System in Primate Embryonic Stem Cell Lines , 2006, Stem cells.

[31]  S. Kasparov,et al.  GAL4-NF-kappaB fusion protein augments transgene expression from neuronal promoters in the rat brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  R. Mandel,et al.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. , 2007, Current gene therapy.

[33]  M. Oshimura,et al.  Correction of a genetic defect in multipotent germline stem cells using a human artificial chromosome , 2008, Gene Therapy.

[34]  M. Carey,et al.  Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging , 2008, Gene Therapy.

[35]  Su-Chun Zhang,et al.  Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. , 2007, Stem cells and development.

[36]  Erwin G. Van Meir,et al.  Erratum: Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4 (Cancer Research (2007) 67, (6872-6881)) , 2007 .

[37]  D. Bartlett,et al.  Development of a melanoma-specific adenovirus. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  George Q. Daley,et al.  Prospects for Stem Cell-Based Therapy , 2008, Cell.

[39]  M. Oshimura,et al.  Human artificial chromosome vectors meet stem cells: new prospects for gene delivery. , 2006, Stem cell reviews.

[40]  Erwin G. Van Meir,et al.  Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. , 2007, Cancer research.

[41]  S. Kyo,et al.  A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. , 2000, Human gene therapy.

[42]  Knut Stieger,et al.  Immune responses to gene product of inducible promoters. , 2007, Current gene therapy.

[43]  R. Cortese,et al.  Gene therapy progress and prospects: transcription regulatory systems , 2004, Gene Therapy.

[44]  E. Lou,et al.  An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16 , 2007, Cancer Gene Therapy.

[45]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[46]  T. Akhurst,et al.  Tumor-specific transcriptional targeting of suicide gene therapy , 2002, Gene Therapy.

[47]  D. Hallahan,et al.  Ionizing radiation activates transcription of the EGR1 gene via CArG elements. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Cannon,et al.  Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. , 2007, Human gene therapy.

[49]  J. Bruder,et al.  Promoters influence the kinetics of transgene expression following adenovector gene delivery , 2008, The journal of gene medicine.

[50]  H. Mizuguchi,et al.  Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  V. Sandig,et al.  Reactivation of the Previously Silenced Cytomegalovirus Major Immediate-Early Promoter in the Mouse Liver: Involvement of NFκB , 1998, Journal of Virology.

[52]  R. Weichselbaum,et al.  TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Scott,et al.  The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation , 2008, Gene Therapy.

[54]  Douglas B. Evans,et al.  Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. , 2007, Cancer cell.

[55]  Y Wang,et al.  A regulatory system for use in gene transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K. Jooss,et al.  Stable antibody expression at therapeutic levels using the 2A peptide , 2005, Nature Biotechnology.

[57]  K. Matthaei Genetically manipulated mice: a powerful tool with unsuspected caveats , 2007, The Journal of physiology.

[58]  Melisa L. Budde,et al.  Generation and characterization of novel tetracycline-inducible pancreatic transcription factor-expressing murine embryonic stem cell lines. , 2006, Stem cells and development.

[59]  Matthias Schieker,et al.  Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer , 2008, Journal of cellular and molecular medicine.

[60]  D. Nettelbeck,et al.  Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. , 2004, Molecular cancer therapeutics.

[61]  M. Dewhirst,et al.  A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas , 2007, Molecular Cancer Therapeutics.

[62]  N. Senzer,et al.  TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up , 2005, Annals of Surgical Oncology.

[63]  N. Vilaboa,et al.  Regulatable gene expression systems for gene therapy. , 2006, Current gene therapy.

[64]  Shannon R. Magari,et al.  A humanized system for pharmacologic control of gene expression , 1996, Nature Medicine.

[65]  Hoguen Kim,et al.  Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. , 2003, Human gene therapy.

[66]  Sinae Kim,et al.  Efficiency of the elongation factor-1alpha promoter in mammalian embryonic stem cells using lentiviral gene delivery systems. , 2007, Stem cells and development.

[67]  E. Chiocca,et al.  Oncolytic viruses driven by tumor-specific promoters. , 2007, Current cancer drug targets.

[68]  L. Wang,et al.  Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter , 2006, Cancer Gene Therapy.

[69]  Masa Tsuchiya,et al.  Sequential Logic Model Deciphers Dynamic Transcriptional Control of Gene Expressions , 1997, PloS one.

[70]  Su-Chun Zhang,et al.  In Vitro‐ and In Vivo‐Induced Transgene Expression in Human Embryonic Stem Cells and Derivatives , 2008, Stem cells.

[71]  S. Rocha Gene regulation under low oxygen: holding your breath for transcription. , 2007, Trends in biochemical sciences.

[72]  M. Manns,et al.  A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. , 2003, Cancer research.

[73]  R. Evans,et al.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  P. Schlag,et al.  Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter–regulated tumor necrosis factor-α expression , 2007, Molecular Cancer Therapeutics.

[75]  Soonsang Yoon,et al.  Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  H. Mizuguchi,et al.  Efficient adenovirus vector‐mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation , 2008, The journal of gene medicine.

[77]  G. Fuller,et al.  The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells , 2000, Nature Medicine.

[78]  K. Shirouzu,et al.  An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice , 2003, Hepatology.

[79]  Ren-Ke Li,et al.  Human CMV immediate‐early enhancer: a useful tool to enhance cell‐type‐specific expression from lentiviral vectors , 2008, The journal of gene medicine.

[80]  Samuel Hellman,et al.  Spatial and temporal control of gene therapy using ionizing radiation , 1995, Nature Medicine.

[81]  P. Pasceri,et al.  Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[82]  S. Scott,et al.  Hypoxia- and radiation-activated Cre/loxP ‘molecular switch’ vectors for gene therapy of cancer , 2006, Gene Therapy.

[83]  A. Hochberg,et al.  Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  C. Barcia,et al.  Regulatable gene expression systems for gene therapy applications: progress and future challenges. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  G. Vassaux,et al.  Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. , 2007, Cancer research.

[86]  H. Fang,et al.  Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.

[87]  I. Alexander,et al.  Bidirectional promoter interference between two widely used internal heterologous promoters in a late-generation lentiviral construct , 2008, Gene Therapy.

[88]  L. Wang,et al.  Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. , 1996, Gene therapy.

[89]  R. Weichselbaum,et al.  Transcriptional control of viral gene therapy by cisplatin. , 2002, The Journal of clinical investigation.

[90]  J. Reiser,et al.  Tight control of transgene expression by lentivirus vectors containing second‐generation tetracycline‐responsive promoters , 2005, The journal of gene medicine.

[91]  Dexi Liu,et al.  Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. , 2006, Biochemical and biophysical research communications.

[92]  C. Heeschen,et al.  Genetically engineered stem cells for therapeutic gene delivery. , 2007, Current gene therapy.

[93]  Z. Guo,et al.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. , 2008, Biochimica et biophysica acta.

[94]  Focal Gene Induction in the Liver of Rats by a Heat-Inducible Promoter Using Focused Ultrasound Hyperthermia: Preliminary Results , 2005, Investigative radiology.

[95]  M. Imhof,et al.  Reversal of the silencing of tetracycline‐controlled genes requires the coordinate action of distinctly acting transcription factors , 2005, The journal of gene medicine.

[96]  R. Weichselbaum,et al.  Ionizing radiation: a genetic switch for cancer therapy , 2006, Cancer Gene Therapy.

[97]  S. Orkin,et al.  Site-directed, virus-free, and inducible RNAi in embryonic stem cells , 2007, Proceedings of the National Academy of Sciences.

[98]  K. Irvine,et al.  De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. , 2006, Cancer research.

[99]  I. Delgado-Enciso,et al.  A potent replicative delta‐24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms , 2007, The journal of gene medicine.

[100]  J. Gu,et al.  Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. , 2000, Cancer research.